Shire (NASDAQ:SHPG) had its price target trimmed by B. Riley from $201.00 to $181.00 in a research note released on Friday, MarketBeat.com reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. B. Riley also issued estimates for Shire’s Q1 2018 earnings at $3.75 EPS, Q2 2018 earnings at $3.68 EPS, Q3 2018 earnings at $3.78 EPS, Q4 2018 earnings at $4.07 EPS, FY2019 earnings at $17.50 EPS, FY2020 earnings at $19.00 EPS, FY2021 earnings at $20.00 EPS and FY2022 earnings at $21.00 EPS.
A number of other analysts have also recently commented on SHPG. FBR & Co initiated coverage on Shire in a research note on Thursday, October 19th. They issued a buy rating and a $201.00 price target for the company. Zacks Investment Research cut Shire from a hold rating to a sell rating in a research note on Friday, October 20th. ValuEngine raised Shire from a hold rating to a buy rating in a research note on Thursday, October 26th. Piper Jaffray Companies reaffirmed a hold rating and issued a $160.00 price target on shares of Shire in a research note on Friday, October 27th. Finally, Cantor Fitzgerald reissued a buy rating and set a $222.00 target price on shares of Shire in a research note on Friday, October 27th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus price target of $209.23.
Shares of Shire (NASDAQ:SHPG) opened at $134.06 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.98 and a quick ratio of 0.52. The company has a market capitalization of $40,900.00, a PE ratio of 6.12, a PEG ratio of 0.75 and a beta of 1.41. Shire has a 52 week low of $123.73 and a 52 week high of $192.15.
Shire (NASDAQ:SHPG) last announced its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported $3.98 EPS for the quarter, beating analysts’ consensus estimates of $3.86 by $0.12. The company had revenue of $4.14 billion during the quarter, compared to analysts’ expectations of $4.01 billion. Shire had a return on equity of 14.75% and a net margin of 28.17%. Shire’s revenue was up 8.9% on a year-over-year basis. During the same period in the prior year, the business posted $3.37 EPS. sell-side analysts predict that Shire will post 15.27 earnings per share for the current year.
The firm also recently announced a semiannual dividend, which will be paid on Tuesday, April 24th. Investors of record on Friday, March 9th will be paid a dividend of $0.8937 per share. This represents a yield of 1.33%. This is a boost from Shire’s previous semiannual dividend of $0.15. The ex-dividend date of this dividend is Thursday, March 8th. Shire’s dividend payout ratio is presently 4.20%.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. SeaCrest Wealth Management LLC acquired a new position in Shire during the 4th quarter worth approximately $107,000. Amica Retiree Medical Trust acquired a new position in Shire during the 4th quarter worth approximately $120,000. BB&T Investment Services Inc. boosted its position in Shire by 1,672.3% during the 3rd quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 786 shares during the last quarter. Avestar Capital LLC acquired a new position in Shire during the 4th quarter worth approximately $116,000. Finally, Steward Partners Investment Advisory LLC acquired a new position in Shire during the 3rd quarter worth approximately $159,000. 20.74% of the stock is owned by institutional investors and hedge funds.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.